The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436).

Georgina V. Long

Consultant or Advisory Role - GlaxoSmithKline; GlaxoSmithKline

Other Remuneration - GlaxoSmithKline; GlaxoSmithKline

Paolo Antonio Ascierto

Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Roche/Genentech

Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche/Genentech

Jean Jacques Grob

Consultant or Advisory Role - GlaxoSmithKline

Honoraria - GlaxoSmithKline

Omid Hamid

Honoraria - Bristol-Myers Squibb

Research Funding - Bristol-Myers Squibb

Richard Kefford

Consultant or Advisory Role - GlaxoSmithKline

Celeste Lebbe

No relevant relationships to disclose

David R. Minor

No relevant relationships to disclose

Antoni Ribas

Consultant or Advisory Role - Roche/Genentech

Honoraria - GlaxoSmithKline

Dirk Schadendorf

Consultant or Advisory Role - GlaxoSmithKline

Honoraria - GlaxoSmithKline

Leslie Anne Fecher

Consultant or Advisory Role - Bristol-Myers Squibb (U)

Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Immunogen; Novartis; Roche/Genentech

Other Remuneration - GlaxoSmithKline

Uwe Trefzer

Consultant or Advisory Role - GlaxoSmithKline

Nikita Arya